LITTLE FALLS, N.J., Jan. 18, 2011 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, reports that the company received positive feedback from attendees following their presentations at the OneMedForum conference in San Francisco last week. Presenting at the conference was CEO Randall McCoy and senior Board Members Dr. Joseph Rubinfeld and Dr. Craig Eagle.
Regenicin presented its unique business model at the conference including its core business strategy for 2011. Key components of Regenicin's strategy included identifying promising new therapeutic candidates that address unmet needs in growing markets; developing the most strategic, economical and expeditious pathways for achieving regulatory approval by the FDA; and creating a commercialization pipeline for bringing new candidates to market once FDA approval can be obtained.
Regenicin board member, Dr. Rubinfeld, who was an initial founder of Amgen and Supergen stated that: "I was very pleased to be present and interact with the professionals at the forum. The feedback was largely positive and very informative."
Regenicin board member and consultant, Dr. Craig Eagle, a senior executive at Pfizer's, also stated, "After hearing the positive feedback at the conference, I'm very enthusiastic about our future and what the new year holds for our business."
According to Regenicin's CEO, Randall McCoy, the burn treatment market in the US is a $3 Billion Dollar opportunity for the company. This coupled with a strong management team and board of directors, optimally positions Regenicin to achieve its corporate goals and mission in 2011-2012.
Regenicin, Inc., (www.regenicin.com) is a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is playing a critical role in developing an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. The company is publicly traded with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Regenicin, Inc.